The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms
Keeps Halo Pharma to drive independent growth
Both join the leading CRDMO’s executive committee to drive global people strategy and commercial expansion
Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
Bulling brings extensive experience across the biopharma and CDMO landscape, with leadership roles spanning both drug substance and drug product operations
OneSource is the contract development and manufacturing organization (CDMO) partner for this product
Zero-observation outcomes strengthen global credibility and accelerate CDMO ambitions
The goal is to better support drug developers as programs move from laboratory research into clinical trials
CRDMO plans to add 800–1,000 women across scientific and leadership roles over three years
Subscribe To Our Newsletter & Stay Updated
